Byong Kim
Director/Board Member at LIPELLA PHARMACEUTICALS INC.
Net worth: 33 440 $ as of 30/05/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jonathan Kaufman | M | 58 | 19 years | |
| B. Christopher Kim | M | - | 8 years | |
| David Harel | M | - |
CytoReason Ltd.
 CytoReason Ltd. Information Technology ServicesTechnology Services CytoReason Ltd. is an Israeli company that aims to link mechanisms across diseases, treatments, and patient groups. The company is based in Tel Aviv-Yafo, Israel. The company provides a platform that connects decisions to the underlying science of drug programs. The company's team includes top immunologists, a chief medical officer, a chief data scientist, a VP of strategic alliances, a chief technology officer, and a head of commercial operations. The company focuses on immune-mediated diseases such as inflammatory bowel disease, atopic dermatitis, rheumatoid arthritis, and asthma, immuno-oncology diseases such as non-small cell lung cancer, renal cell carcinoma, and melanoma, and fibrosis diseases such as non-alcoholic steatohepatitis, systemic sclerosis, and idiopathic pulmonary fibrosis. CytoReason was founded in 2016 by Elina Starosvetsky, Ksenya Kveler, Yuval Kalugny, Renaud Gaujoux, David Harel, and Shai Shen-Orr. David Harel has been the CEO since 2016. | 8 years |
| Michael Chancellor | M | 67 | 19 years | |
| Shai Shen-Orr | M | - |
CytoReason Ltd.
CytoReason Ltd. Information Technology ServicesTechnology Services CytoReason Ltd. is an Israeli company that aims to link mechanisms across diseases, treatments, and patient groups. The company is based in Tel Aviv-Yafo, Israel. The company provides a platform that connects decisions to the underlying science of drug programs. The company's team includes top immunologists, a chief medical officer, a chief data scientist, a VP of strategic alliances, a chief technology officer, and a head of commercial operations. The company focuses on immune-mediated diseases such as inflammatory bowel disease, atopic dermatitis, rheumatoid arthritis, and asthma, immuno-oncology diseases such as non-small cell lung cancer, renal cell carcinoma, and melanoma, and fibrosis diseases such as non-alcoholic steatohepatitis, systemic sclerosis, and idiopathic pulmonary fibrosis. CytoReason was founded in 2016 by Elina Starosvetsky, Ksenya Kveler, Yuval Kalugny, Renaud Gaujoux, David Harel, and Shai Shen-Orr. David Harel has been the CEO since 2016. | 8 years |
| Douglas Johnston | M | 40 | 3 years | |
| Naoki Yoshimura | M | 67 | 3 years | |
| Ryan Pruchnic | M | 50 | 3 years | |
| Eyal Desheh | M | 72 |
CytoReason Ltd.
CytoReason Ltd. Information Technology ServicesTechnology Services CytoReason Ltd. is an Israeli company that aims to link mechanisms across diseases, treatments, and patient groups. The company is based in Tel Aviv-Yafo, Israel. The company provides a platform that connects decisions to the underlying science of drug programs. The company's team includes top immunologists, a chief medical officer, a chief data scientist, a VP of strategic alliances, a chief technology officer, and a head of commercial operations. The company focuses on immune-mediated diseases such as inflammatory bowel disease, atopic dermatitis, rheumatoid arthritis, and asthma, immuno-oncology diseases such as non-small cell lung cancer, renal cell carcinoma, and melanoma, and fibrosis diseases such as non-alcoholic steatohepatitis, systemic sclerosis, and idiopathic pulmonary fibrosis. CytoReason was founded in 2016 by Elina Starosvetsky, Ksenya Kveler, Yuval Kalugny, Renaud Gaujoux, David Harel, and Shai Shen-Orr. David Harel has been the CEO since 2016. | - |
| Elina Starosvetsky | M | - |
CytoReason Ltd.
CytoReason Ltd. Information Technology ServicesTechnology Services CytoReason Ltd. is an Israeli company that aims to link mechanisms across diseases, treatments, and patient groups. The company is based in Tel Aviv-Yafo, Israel. The company provides a platform that connects decisions to the underlying science of drug programs. The company's team includes top immunologists, a chief medical officer, a chief data scientist, a VP of strategic alliances, a chief technology officer, and a head of commercial operations. The company focuses on immune-mediated diseases such as inflammatory bowel disease, atopic dermatitis, rheumatoid arthritis, and asthma, immuno-oncology diseases such as non-small cell lung cancer, renal cell carcinoma, and melanoma, and fibrosis diseases such as non-alcoholic steatohepatitis, systemic sclerosis, and idiopathic pulmonary fibrosis. CytoReason was founded in 2016 by Elina Starosvetsky, Ksenya Kveler, Yuval Kalugny, Renaud Gaujoux, David Harel, and Shai Shen-Orr. David Harel has been the CEO since 2016. | 8 years |
| Robert Moldwin | M | - | - | |
| Joseph Janicki | M | - | - | |
| Michelle Gruber | F | - | 15 years | |
| Janet Okonski | F | - | 3 years | |
| Allison Houck | F | - | - | |
| Daniel Cohen | M | 60 | 1 years | |
| Katie Johnston | F | - | - | |
| Lori Birder | M | 64 | 1 years | |
| Tomohiro Ueda | M | - | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| David Battleman | M | 57 | 15 years | |
| Min-Sik Shin | M | - | 2 years | |
| Jiwoong Chun | M | - | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 16 | 72.73% |
| Israel | 4 | 18.18% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Byong Kim
- Personal Network
